Centers for Disease Control and Prevention

National Center for Immunization and Respiratory Diseases

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Zoster Vaccines Session: Introduction

ACIP Meeting

June 25, 2021

Grace Lee, MD, MPH

ACIP Chair, Herpes Zoster Work Group
2021 Herpes Zoster Work Group

2

ACIP Members

Grace Lee, MD, MPH (Chair)

Lynn Bahta, RN, MPH

Camille Kotton, MD

Ex Officio Members

Paula Agger, MD, MPH FDA

Jeffrey Cohen, MD NIH

Darcie Everett, MD, MPH FDA

Jeffrey Kelman, MD CMS

Liaison Representatives

Carol Baker, MD IDSA

Mary Pat Friedlander, MD AAFP

Sandra Fryhofer, MD ACP/AMA

Elizabeth Rausch-Phung, MD, MPH AIM

William Schaffner, MD NFID

Kenneth Schmader, MD AGS

Adam Welch, PharmD APhA

Invited Consultants

Robin Avery, MD

Edward Belongia, MD

Al Benson, MD

Paul Cieslak, MD

Jeffrey Curtis, MD, MPH

Jay Fishman, MD

Rafael Harpaz, MD, MPH

Kelly Moore, MD, MPH

Vicki Morrison, MD

Steven Pergam, MD

Lisa Prosser, PhD

CDC Lead

Tara Anderson, DVM, MPH, PhD
Timeline of Recombinant Zoster Vaccine (RZV, Shingrix)

Oct 2017

FDA 

licensure

Jan 2018

CDC adopts ACIP 

recommendation

Aug 2020

European Medicines Agency 

approves expanded RZV 

indication (adults ≥18y at 

increased risk of HZ)

Fall 2020 

Supplemental biologics license 

application submitted to FDA to support 

RZV use in IC adults ≥18y

Feb 2021

RZV in IC policy question 

and EtR introduced to ACIP

3

Abbreviations: HZ-Herpes Zoster; ZVL-Zoster Vaccine Live; RZV: Recombinant Zoster Vaccine; EtR-Evidence to 

Recommendations Framework

Clinical trials and evidence generation involving use of RZV among 

immunocompromised populations
▪ Population: IC adults ≥19 years of age; split into two parts 

(19–49 years, ≥50 years)

▪ Intervention: RZV, 2 doses at least 4 weeks apart

▪ Comparison: No vaccine

▪ Outcomes

Policy question: “Should vaccination with RZV be recommended 

for immunocompromised adults 19 years of age and older?”

4
▪ Six work group meetings

▪ Review and discussed

–GSK’s Clinical Program regarding use of RZV in IC populations

–Economic assessments regarding use of RZV in IC populations

Activities since February 2021 ACIP Meeting

5
▪ Burden of HZ in 

IC Adults

▪ Use of RZV in IC 

Populations: 

Overview of 

Clinical Program

▪ Discussion

Agenda for Today’s Session

6
▪ ACIP HZWG: Paula Agger, Robin Avery, Lynn Bahta, Carol Baker, Edward Belongia, Al 

Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Jeff Duchin, Darcie Everett, Jay Fishman, 

Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Jeff Kelman, Camille Kotton, 

Vicki Morrison, Kelly Moore, Steve Pergam, Lisa Prosser, Elizabeth Rausch-Phung, Bill 

Schaffner, Ken Schmader, Adam Welch

▪ HZWG CDC Lead: Tara Anderson

▪ CDC, Other Contributors: Jessica Anderson, Stephanie Bialek, Tom Clark, Amanda 

Cohn, Kathleen Dooling, Jonathan Duffy, Richard Forshee, Angela Guo, Theresa 

Harrington, Alexandra Hess, Lisa Jackson, Jessica Leung, Shainoor Ismail, Tara Jatlaoui, 

Andrew Kroger, Andrew Leidner, Mona Marin, Karen Mason, Jennifer Nelson, Paul 

Rota, Ismael Ortega-Sanchez, Coleman Rotstein, Jeanne Santoli, Tom Shimabukuro, 

John Su, Megan Wallace, Eric Weintraub

Acknowledgments

7
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank You